NCT00379483

Extension Study of Iron Chelation Therapy With Deferasirox in Patients With Transfusional Iron Overload

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 66 (actual)
• Sponsor: Novartis Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

A 1-year randomized Phase IIa core trial followed by a prolongation of 5 to 9 months was conducted to investigate the efficacy and safety of deferasirox in patients aged ≥ 18 years with transfusion-dependent iron overload. The objective of this extension study is to assess the long-term safety of deferasirox and to provide treatment in patients with transfusional iron overload.

Conditions

• Transfusional Iron Overload

Interventions

Type	Name	Description
DRUG	Deferasirox

Timeline

• Start date: 2002-07-01
• Primary completion: 2003-04-01
• Completion: 2003-04-01
• First posted: 2006-09-22
• Last updated: 2015-03-19

Locations

4 sites across 1 country: Italy